Do analysts prefer GYRE or MOR?

Gyre Therapeutics presently has a consensus target price of $16.00, suggesting a potential upside of 137.74%. Given Gyre Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Gyre Therapeutics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GYRE or MOR more profitable?

Gyre Therapeutics has a net margin of -15.47% compared to MorphoSys' net margin of -226.79%. Gyre Therapeutics' return on equity of -6.57% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets Gyre Therapeutics -15.47% -6.57% -5.35% MorphoSys -226.79% -694.31% -22.55%

Gyre Therapeutics (GYRE) Competitors

$6.73 -0.01 (-0.15%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$6.72 -0.01 (-0.07%)

As of 09/11/2026 07:30 PM Eastern

Compare

GYRE vs. ARQT, MBX, MOR, ATAI, and SUPN

Should you buy Gyre Therapeutics stock or one of its competitors? Gyre Therapeutics's main competitors and comparable companies include Arcutis Biotherapeutics (ARQT), MBX Biosciences (MBX), MorphoSys (MOR), Atai Beckley (ATAI), and Supernus Pharmaceuticals (SUPN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Gyre Therapeutics compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Gyre Therapeutics (NASDAQ:GYRE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

24.0% of Gyre Therapeutics shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Arcutis Biotherapeutics presently has a consensus target price of $35.57, indicating a potential upside of 48.90%. Gyre Therapeutics has a consensus target price of $16.00, indicating a potential upside of 137.74%. Given Gyre Therapeutics' higher probable upside, analysts clearly believe Gyre Therapeutics is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Arcutis Biotherapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

Gyre Therapeutics has lower revenue, but higher earnings than Arcutis Biotherapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	7.98	-$16.14M	$0.21	113.76
Gyre Therapeutics	$116.59M	6.44	$5.03M	-$0.21	N/A

In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Gyre Therapeutics. MarketBeat recorded 6 mentions for Arcutis Biotherapeutics and 1 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.80 beat Arcutis Biotherapeutics' score of 1.19 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Arcutis Biotherapeutics	Positive
Gyre Therapeutics	Very Positive

Arcutis Biotherapeutics has a net margin of 6.15% compared to Gyre Therapeutics' net margin of -15.47%. Arcutis Biotherapeutics' return on equity of 15.05% beat Gyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

Summary

Arcutis Biotherapeutics beats Gyre Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Gyre Therapeutics compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Gyre Therapeutics (NASDAQ:GYRE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Gyre Therapeutics has higher revenue and earnings than MBX Biosciences. Gyre Therapeutics is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Gyre Therapeutics	$116.59M	6.44	$5.03M	-$0.21	N/A

MBX Biosciences currently has a consensus price target of $77.00, indicating a potential upside of 30.46%. Gyre Therapeutics has a consensus price target of $16.00, indicating a potential upside of 137.74%. Given Gyre Therapeutics' higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, MBX Biosciences had 3 more articles in the media than Gyre Therapeutics. MarketBeat recorded 4 mentions for MBX Biosciences and 1 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.80 beat MBX Biosciences' score of 1.09 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MBX Biosciences	Positive
Gyre Therapeutics	Very Positive

MBX Biosciences has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

MBX Biosciences has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -15.47%. Gyre Therapeutics' return on equity of -6.57% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

24.0% of Gyre Therapeutics shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Gyre Therapeutics beats MBX Biosciences on 9 of the 16 factors compared between the two stocks.

How does Gyre Therapeutics compare to MorphoSys?

Gyre Therapeutics (NASDAQ:GYRE) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Gyre Therapeutics has a net margin of -15.47% compared to MorphoSys' net margin of -226.79%. Gyre Therapeutics' return on equity of -6.57% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-15.47%	-6.57%	-5.35%
MorphoSys	-226.79%	-694.31%	-22.55%

Gyre Therapeutics presently has a consensus target price of $16.00, suggesting a potential upside of 137.74%. Given Gyre Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Gyre Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Gyre Therapeutics has higher earnings, but lower revenue than MorphoSys. Gyre Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.44	$5.03M	-$0.21	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Gyre Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

In the previous week, Gyre Therapeutics had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for Gyre Therapeutics and 0 mentions for MorphoSys. Gyre Therapeutics' average media sentiment score of 1.80 beat MorphoSys' score of 0.00 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gyre Therapeutics	Very Positive
MorphoSys	Neutral

Summary

Gyre Therapeutics beats MorphoSys on 13 of the 16 factors compared between the two stocks.

How does Gyre Therapeutics compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Gyre Therapeutics (NASDAQ:GYRE) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Atai Beckley currently has a consensus target price of $10.56, suggesting a potential upside of 43.62%. Gyre Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 137.74%. Given Gyre Therapeutics' higher probable upside, analysts plainly believe Gyre Therapeutics is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Atai Beckley had 3 more articles in the media than Gyre Therapeutics. MarketBeat recorded 4 mentions for Atai Beckley and 1 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.80 beat Atai Beckley's score of 0.75 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Atai Beckley	Positive
Gyre Therapeutics	Very Positive

Gyre Therapeutics has higher revenue and earnings than Atai Beckley. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A
Gyre Therapeutics	$116.59M	6.44	$5.03M	-$0.21	N/A

Gyre Therapeutics has a net margin of -15.47% compared to Atai Beckley's net margin of -14,938.36%. Gyre Therapeutics' return on equity of -6.57% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 19.8% of Atai Beckley shares are held by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Atai Beckley has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Summary

Gyre Therapeutics beats Atai Beckley on 10 of the 17 factors compared between the two stocks.

How does Gyre Therapeutics compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Gyre Therapeutics (NASDAQ:GYRE) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Supernus Pharmaceuticals currently has a consensus target price of $62.83, suggesting a potential upside of 50.90%. Gyre Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 137.74%. Given Gyre Therapeutics' higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

24.0% of Gyre Therapeutics shares are held by institutional investors. 8.5% of Supernus Pharmaceuticals shares are held by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Supernus Pharmaceuticals had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 2 mentions for Supernus Pharmaceuticals and 1 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.80 beat Supernus Pharmaceuticals' score of 1.04 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Supernus Pharmaceuticals	Positive
Gyre Therapeutics	Very Positive

Supernus Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

Gyre Therapeutics has lower revenue, but higher earnings than Supernus Pharmaceuticals. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$830.44M	2.91	-$38.55M	-$1.92	N/A
Gyre Therapeutics	$116.59M	6.44	$5.03M	-$0.21	N/A

Supernus Pharmaceuticals has a net margin of -13.23% compared to Gyre Therapeutics' net margin of -15.47%. Supernus Pharmaceuticals' return on equity of 11.13% beat Gyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

Summary

Supernus Pharmaceuticals and Gyre Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Gyre Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GYRE vs. The Competition

Export

Metric	Gyre Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$750.46M	$12.41B	$7.16B	$12.85B
Dividend Yield	N/A	2.64%	2.57%	11.17%
P/E Ratio	-32.05	799.75	274.94	25.36
Price / Sales	6.44	960.74	685.44	117.05
Price / Cash	30.29	88.17	76.65	51.52
Price / Book	4.55	10.39	10.33	6.20
Net Income	$5.03M	$2.85B	$3.50B	$358.50M
7 Day Performance	-1.90%	-3.61%	-3.32%	-2.35%
1 Month Performance	2.91%	0.72%	-0.53%	-3.23%
1 Year Performance	-14.05%	3.61%	23.51%	8.79%

Gyre Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GYRE Gyre Therapeutics	2.1146 of 5 stars	$6.73 -0.1%	$16.00 +137.7%	-14.0%	$750.46M	$116.59M	N/A	40	Positive News
ARQT Arcutis Biotherapeutics	3.8912 of 5 stars	$24.39 +2.1%	$35.57 +45.8%	+38.2%	$3.00B	$463.98M	116.15	150	Positive News Analyst Downgrade Insider Trade Gap Down High Trading Volume
MBX MBX Biosciences	2.8654 of 5 stars	$62.99 +2.1%	$77.00 +22.2%	+445.0%	$2.97B	N/A	N/A	N/A	Positive News
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
ATAI Atai Beckley	2.7622 of 5 stars	$7.28 -1.5%	$10.56 +45.0%	N/A	$2.74B	$4.09M	N/A	80	News Coverage Analyst Upgrade Options Volume High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GYRE) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gyre Therapeutics (GYRE) Competitors

GYRE vs. ARQT, MBX, MOR, ATAI, and SUPN

How does Gyre Therapeutics compare to Arcutis Biotherapeutics?

Summary

How does Gyre Therapeutics compare to MBX Biosciences?

Summary

How does Gyre Therapeutics compare to MorphoSys?

Summary

How does Gyre Therapeutics compare to Atai Beckley?

Summary

How does Gyre Therapeutics compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE vs. The Competition

Gyre Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gyre Therapeutics (GYRE) Competitors

GYRE vs. ARQT, MBX, MOR, ATAI, and SUPN

How does Gyre Therapeutics compare to Arcutis Biotherapeutics?

Do institutionals & insiders believe in ARQT or GYRE?

Do analysts rate ARQT or GYRE?

Which has more risk & volatility, ARQT or GYRE?

Which has stronger valuation and earnings, ARQT or GYRE?

Does the media refer more to ARQT or GYRE?

Is ARQT or GYRE more profitable?

Summary

How does Gyre Therapeutics compare to MBX Biosciences?

Which has higher earnings and valuation, MBX or GYRE?

Do analysts prefer MBX or GYRE?

Does the media prefer MBX or GYRE?

Which has more volatility and risk, MBX or GYRE?

Is MBX or GYRE more profitable?

Do insiders & institutionals believe in MBX or GYRE?

Summary

How does Gyre Therapeutics compare to MorphoSys?

Do institutionals and insiders have more ownership in GYRE or MOR?

Is GYRE or MOR more profitable?

Do analysts prefer GYRE or MOR?

Which has better earnings & valuation, GYRE or MOR?

Which has more risk & volatility, GYRE or MOR?

Does the media refer more to GYRE or MOR?

Summary

How does Gyre Therapeutics compare to Atai Beckley?

Do analysts recommend ATAI or GYRE?

Does the media prefer ATAI or GYRE?

Which has preferable earnings & valuation, ATAI or GYRE?

Is ATAI or GYRE more profitable?

Do institutionals & insiders have more ownership in ATAI or GYRE?

Which has more volatility and risk, ATAI or GYRE?

Summary

How does Gyre Therapeutics compare to Supernus Pharmaceuticals?

Do analysts recommend SUPN or GYRE?

Do insiders & institutionals have more ownership in SUPN or GYRE?

Does the media prefer SUPN or GYRE?

Which has more risk & volatility, SUPN or GYRE?

Which has stronger valuation & earnings, SUPN or GYRE?

Is SUPN or GYRE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE vs. The Competition

Gyre Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools